Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Novartis Ag

Other

Philipp Lustenberger

Klaus Rudolf

Dirk Stenkamp

Stephan Georg Mueller

Kirsten Arndt

Henri Doods

Gerhard Schaenzle

Marco Santagostino

Ingo Konetzki

Thierry Bouyssou

Andreas Schnapp

Christoph Hoenke

Marcus Schindler

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Kurt Schromm

Leo Thomas

Robin Alec Fairhurst

Peter Sieger

Dieter Wiedenmayer

Bernhard Erb

Juergen Mack

Jianguang Zhou

Ralf Lotz

Arnaud Grandeury

Kai Gerlach

Rudolf Hurnaus

Matthias Grauert

Georg Speck

Gottfried Sedelmeier

Michael Paul Pieper

Steffen Breitfelder

Enzo Cereda

Murat Acemoglu

Fabrice Gallou

Michel Pairet

Fabio Paleari

Alexander Dreyer

Sabine Pestel

Eckhart Bauer

Frank Buettner

Claudia Heine

Hermann Schollenberger

Thomas Ullrich

Ralf R H Lotz

Nicola Tufilli

Shinji Hatakeyama

Magdalena Koziczak-Holbro

Bernd Ulrich Riebesehl

Xiang Wu

Xinzhong Lai

Jun Cao

Martin Lenter

Christian Mathes

Beat Schmitz

Gerhard Penn

Bernard Riss

Zhongbo Fei

Ernst Kuesters

Thierry Schlama

Heike-Andrea Wieland

Massimo Moratto

Kristen Arndt

Zichen Jia

Marie Meyer

Qiangbiao Pan

Benli Zou

Ralf R Lotz

Gerald Jurgen Roth

Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.

Crystalline form of LNP023

This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.

Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Benzothiazolone compound

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers.

Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof

A pharmaceutical composition comprising a compound of formula 1 wherein:

Medicaments for the treatment of chronic obstructive pulmonary disease

Enantiomerically pure compounds of general formula 1 wherein the groups R, R, R, R, and Xmay have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claimthe tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, Rand Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula I wherein R, R, Rand Rare as defined in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

The invention relates to compounds of general formula 1 wherein n, A, B, D, L, R, R, Rand Rmay have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Long acting bronchodilators for the treatment of respiratory diseases

Growing community of inventors

Warthausen, Germany

Philipp Lustenberger